Skip to main content
main-content

Supportive care and survivorship

News and opinion

03-10-2019 | Small-cell lung cancer | ESMO 2019 | News

CASPIAN: Adding durvalumab to chemotherapy improves SCLC PROs

The combination of durvalumab plus chemotherapy is associated with better patient-reported outcomes than chemotherapy alone, suggests data from the CASPIAN trial comprising treatment-naïve individuals with extensive-stage small-cell lung cancer.

06-09-2019 | Vaccines | News

Influenza vaccine effective in cancer patients

The influenza vaccine has “modest” effectiveness in patients with cancer, say researchers who believe their findings support public health recommendations for vaccination in this population.

20-08-2019 | Nausea and vomiting | News

Study supports use of fosnetupitant in combination with palonosetron for CINV

A phase II trial shows that the intravenous prodrug fosnetupitant in combination with palonosetron reduces chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

05-07-2019 | FDA | News

Many FDA approved drugs fail to deliver on OS, PRO benefit

An analysis of oncology drugs approved by the US FDA shows that nearly half have not shown improvements in either overall survival or patient-reported outcomes.

04-07-2019 | Prostate cancer | News

EBRT has smallest impact on sexual function after prostate cancer diagnosis

Among the potential active treatment options for prostate cancer, external‐beam radiotherapy alone results in the best preservation of sexual function up to 2 years after treatment, population-based study data show.

03-07-2019 | Cancer pain | News

Pain prevalence characterized for US cancer survivors

Chronic pain is prevalent among US survivors of cancer, reveals research published in a letter to JAMA Oncology.

01-06-2019 | Castration-resistant prostate cancer | ASCO 2019 | News

ARAMIS QoL results add support for darolutamide in nonmetastatic CRPC

Men with nonmetastatic castration-resistant prostate cancer enrolled in the ARAMIS trial report favorable quality of life outcomes with darolutamide relative to placebo.

03-05-2019 | EMA | News

Biosimilar pegfilgrastim receives EMA go-ahead, generic cabazitaxel does not

Read more on these announcements here

03-05-2019 | Mesothelioma | News

Mesothelioma survival doubles with radical hemi-thoracic radiotherapy regimen

Switching palliative radiation for high-dose radical hemi-thoracic radiotherapy significantly increases 2-year overall survival among patients with a new diagnosis of malignant pleural mesothelioma, delegates were told at the ESTRO 38 meeting in Milan, Italy.

08-03-2019 | Prostate cancer | News

Hypofractionated RT noninferior to conventional for QoL in low-risk prostate cancer

Hypofractionated radiotherapy is similar to conventional radiotherapy when it comes to health-related quality of life in men with low-risk prostate cancer, according to the RTOG 0415 phase III randomized controlled trial.

06-03-2019 | Castration-resistant prostate cancer | News

Enzalutamide preserves QoL in men with nonmetastatic CRPC

Men with nonmetastatic, castration-resistant prostate cancer receiving enzalutamide maintain their low baseline pain levels and prostate cancer symptom burden and report high health-related quality of life, indicates a patient-reported outcomes analysis of the phase III PROSPER study.

24-01-2019 | Renal cell carcinoma | News

HRQoL greater with nivolumab plus ipilimumab than sunitinib in advanced RCC

Patients with previously untreated intermediate- or poor-risk advanced renal cell carcinoma derive greater health-related quality of life benefits from nivolumab plus ipilimumab than from sunitinib, CheckMate 214 data show.

15-11-2018 | Prostate cancer | Podcast | Audio

Researcher comment: COMPARE study

Hashim Ahmed takes us through the COMPARE study – presented at NCRI 2018 – which showed that men with localized prostate cancer are willing to make accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research (5:36).

Click here for the accompanying news story.

09-11-2018 | Prostate cancer | News

Prostate cancer patients willing to make trade-offs between survival, side effects

Men with a new diagnosis of nonmetastatic prostate cancer say they would accept small reductions in survival odds if that meant fewer side effects and an improved quality of life, suggests the COMPARE study.

10-10-2018 | Chemotherapy | News

Short-term hospitalization, mortality risk varies by palliative chemotherapy regimen

Two independent studies of older patients receiving initial chemotherapy for metastatic breast cancer or non-small-cell lung cancer have found that the risk for hospitalization or death may be predicted by the cytotoxic regimen used.

09-10-2018 | EMA | News

Brigatinib, paclitaxel, biosimilar pegfilgrastims receive EMA approvals

Read more on these decisions here

08-10-2018 | Quality of life | News

Improved PFS does not equate to improved HRQoL in patients with cancer

Progression-free survival should not be used as a surrogate marker for health-related quality of life as there is no correlation between them, results of a systematic review and quantitative analysis of randomized clinical trials show.

02-10-2018 | Non-small cell lung cancer | News

Surgery type may predict long-term opioid use in early-stage NSCLC

Patients who undergo video-assisted thoracoscopic surgery for stage I non-small-cell lung cancer are less likely to become long-term opioid users than their counterparts undergoing the conventional open procedure, findings suggest.

18-09-2018 | Supportive care | News

Allogeneic HSCT-treated patients often receive medically intense end-of-life care

A US research team has found that end-of-life care among individuals who undergo allogeneic hematopoietic stem cell transplantation can often be medically intense.

13-09-2018 | Castration-resistant prostate cancer | News

SPARTAN: Adding apalutamide to ADT does not diminish nonmetastatic CRPC HRQoL

Men with high-risk nonmetastatic castration-resistant prostate cancer do not report a deterioration in health-related quality of life when androgen deprivation therapy is supplemented with apalutamide, indicate SPARTAN trial results.

Image Credits